Welcome to 3TR

Pathobiology-Driven Precision Therapy in RA
(3TR Precis-The-RA) study

3TR consortium

3TR Precis The RA is part of 3TR (Taxonomy, Treatment, Target and Remission) consortium project. The overall aim of the 3TR Project is to provide fundamental new insights into the mechanisms of response and non response to treatment across seven disease areas, one of which is Rheumatoid arthritis (RA).

For further information about the 3TR consortium, please visit their website.

Number of recruits: 7 
Number of sites open: 1 

The new 3TR Trials - The promise of personalised medicine for Rheumatoid Arthritis

An online talk by Costantino Pitzalis (Professor of Rheumatology at Queen Mary University of London) about the research taking place at the Centre for Experimental Medicine and Rheumatology (EMR) took place on 20th March 2023. A recording of this talk will be uploaded soon.

Recruitment Announcement

Exciting News! Our research team is delighted to announce that we have successfully completed all the 3TR visits for the first two participants at Mile End Hospital. We are pleased to inform you that we have successfully recruited a total of seven participants to date.

3tr disclaimer

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking(JU) under grant agreement No 831434.
The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

The content of this website reflects only the author's view and JU is not responsible for any use that may be made of the information it contains.